HomeCERE • NASDAQ
Follow
Cerevel Therapeutics Holdings Inc
Previous close
$41.31
Day range
$41.30 - $41.80
Year range
$19.59 - $43.59
Market cap
7.55B USD
Avg Volume
1.29M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 139.56M | 30.13% |
Net income | -132.66M | -42.94% |
Net profit margin | — | — |
Earnings per share | -0.76 | -28.81% |
EBITDA | -138.06M | -30.30% |
Effective tax rate | -0.14% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 990.96M | 11.09% |
Total assets | 1.24B | 22.15% |
Total liabilities | 569.55M | 14.69% |
Total equity | 673.74M | — |
Shares outstanding | 181.58M | — |
Price to book | 11.13 | — |
Return on assets | -33.79% | — |
Return on capital | -36.71% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -132.66M | -42.94% |
Cash from operations | -97.42M | -11.37% |
Cash from investing | -150.21M | -461.90% |
Cash from financing | 508.37M | 23,756.03% |
Net change in cash | 260.74M | 332.64% |
Free cash flow | -54.91M | -10.03% |
About
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses. Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts.
The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.
In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion. Wikipedia
Founded
2018
Website
Employees
334
